Evidence map›Paper›PMID 29922071›Full record

ArticleOncoTargets and therapy2018

Ablation of MCM10 using CRISPR/Cas9 restrains the growth and migration of esophageal squamous cell carcinoma cells through inhibition of Akt signaling.

Jie Yan, Pan Du, Yongxu Jia, Zhiwei Chang, Silin Gan, Xiaohan Xu, Yaohe Wang, Yanru Qin, Quancheng Kan

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jie YanDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Pan DuNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
Yongxu JiaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhiwei ChangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Silin GanDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaohan XuDepartment of Anesthesiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yaohe WangNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
Yanru QinDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Quancheng KanDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNMolecular Oncology (United States) · USZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMinichromosome maintenance 10 (MCM10) is deregulated in several malignancies including cervical cancer and urothelial carcinoma. However, the expression and biologic role of MCM10 in esophageal squamous cell carcinoma (ESCC) is still unknown.

methodsIn this study, we performed immunohistochemistry and real-time polymerase chain reaction (PCR) analysis to examine the expression of MCM10 in ESCC and adjacent normal esophageal tissues. The associations of MCM10 expression with clinicopathologic parameters of ESCC were analyzed. Ablation of MCM10 through the CRISPR/Cas9 technology was conducted and its impact on ESCC cell growth and migration was investigated.

resultsThe mRNA and protein expression levels of MCM10 were significantly greater in ESCC than in normal tissues (

conclusionIn conclusion, these results suggest that MCM10 acts as an oncogene in ESCC through activation of Akt signaling and represents a promising therapeutic target for this malignancy.

Indexed as

esophageal cancergrowthmigrationminichromosome maintenance proteins

Identifiers

PMID29922071
PMCPMC5995424
OpenAlexW2807321357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.